Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.

Overview of attention for article published in Journal of Clinical Oncology, April 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 17 news outlets
blogs: 1 blog

twitter: 80 X users

Readers on

mendeley: 123 Mendeley

So far, Altmetric has seen 23 news stories from 17 outlets.

First-Line Avelumab Maintenance for Metastatic Urothelial Cancer

MedPage Today, 29 Feb 2024

This Reading Room is a collaboration between MedPage Today® and: Follow-up results from the phase III JAVELIN Bladder 100 trial…

Recap: The Expanding Treatment Paradigm for Urothelial Carcinoma

Cancer Network, 19 Nov 2022

Centering discussion on clinical scenarios of urothelial carcinoma, expert oncologists review recent data and discuss how…

Recap: Clinical Practice Experience With Avelumab First-Line Maintenance in Urothelial Carcinoma

Cancer Network, 31 May 2022

Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients…

Treatment Strategies in Metastatic Urothelial Carcinoma With Immune Checkpoint Inhibitors and Targeted Therapies

Cancer Network, 14 Mar 2022

Daniel P. Petrylak, MD, reviews the current systemic therapy treatment paradigm in metastatic urothelial carcinoma.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 19 additional news stories.